Status and phase
Conditions
Treatments
About
This study is a prospective, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of dapagliflozin in patients with nonobstructive hypertrophic cardiomyopathy (HCM).
Patients with nonobstructive HCM frequently experience exercise intolerance, heart failure symptoms, and impaired quality of life due to diastolic dysfunction and myocardial remodeling. However, effective disease-modifying treatment options remain limited. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated clinical benefits in patients with heart failure and may improve myocardial relaxation, cardiac remodeling, and exercise capacity.
Approximately 440 patients with nonobstructive HCM will be randomized in a 1:1 ratio to receive dapagliflozin 10 mg once daily or matching placebo for 24 weeks. The primary objective is to evaluate the effect of dapagliflozin on exercise capacity as measured by the change in peak oxygen consumption (peak VO₂) from baseline to Week 24. Secondary objectives include evaluation of diastolic function, echocardiographic parameters, heart failure symptoms, serum biomarkers, arrhythmic burden, and cardiac magnetic resonance imaging parameters in a predefined substudy population.
Full description
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy and is characterized by unexplained left ventricular hypertrophy in the absence of abnormal loading conditions. Patients with nonobstructive HCM frequently experience exercise intolerance, dyspnea, and heart failure symptoms despite preserved left ventricular ejection fraction. Impaired left ventricular relaxation and elevated filling pressures are important pathophysiological mechanisms contributing to symptoms and disease progression.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated beneficial cardiovascular effects in patients with heart failure, including improvements in cardiac function, myocardial remodeling, and clinical outcomes. However, the effects of SGLT2 inhibition in patients with nonobstructive HCM have not been adequately investigated.
This study is designed to evaluate the efficacy and safety of enavogliflozin compared with placebo in patients with nonobstructive hypertrophic cardiomyopathy. Eligible participants will be randomized to receive either enavogliflozin or matching placebo in addition to standard medical therapy.
The primary objective is to assess the effect of enavogliflozin on left ventricular diastolic function. Secondary objectives include evaluation of exercise capacity, symptoms, serum biomarkers, and arrhythmic burden. Clinical assessments, laboratory testing, electrocardiography, ambulatory rhythm monitoring, cardiopulmonary exercise testing, and echocardiographic examinations will be performed according to the study schedule to evaluate treatment effects.
The results of this study are expected to provide evidence regarding the potential role of SGLT2 inhibition as a therapeutic strategy for patients with nonobstructive hypertrophic cardiomyopathy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Able to understand the study protocol and provide written informed consent.
Adults aged 19 to 80 years.
Nondiabetic participants or participants with type 2 diabetes mellitus (HbA1c 6.5% to 10.5%).
Patients with nonobstructive hypertrophic cardiomyopathy (HCM) documented by echocardiography performed within 3 months prior to screening, with no significant dynamic left ventricular outflow tract (LVOT) obstruction at rest, during the Valsalva maneuver, or with exercise provocation.
Participants receiving medical therapy for HCM, including beta-blockers, non-dihydropyridine calcium channel blockers, loop diuretics, thiazide or thiazide-like diuretics, mineralocorticoid receptor antagonists, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or angiotensin receptor-neprilysin inhibitors, must have been on a stable dose for at least 2 weeks prior to randomization and be expected to remain on a stable dose throughout the study period.
Women of childbearing potential who agree to use effective contraception
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
440 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Geu-Ru Hong, Professor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal